We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Evidence on botulinum toxin in selected disorders.
Botulinum toxin (BoNT) is a neurotoxin produced by the bacteria Clostridium botulinum that has become widely used for various neurologic indications. The four toxin formulations currently available for use in the United States (approved by the Food and Drug Administration) are onabotulinumtoxinA (Botox® ), abobotulinumtoxinA (Dysport® ), incobotulinumtoxinA (Xeomin® ), and rimabotulinumtoxinB (Myobloc® ). While the FDA-approved labels indicate that potency conversions should not be done, literature supports relative dose equivalents of approximately 1:1:2-4:50-100, respectively. The aim of this paper is to review the evidence on the use of BoNT formulations available in the United States for specific neurologic disorders, including blepharospasm, cervical dystonia (CD), upper and lower extremity spasticity and chronic migraine. Data from the updated 2016 American Academy of Neurology (AAN) guidelines are presented and the level of evidence for use of the four available preparations of BoNT are discussed (Table 2 in appendix). For the management of blepharospasm, the recommendations are for use of onaBoNT-A and incoBoNT-A injections with level B evidence. For the management of CD, the recommendations are for use of aboBoNT-A and rimaBoNT-B with level A evidence. For the management of upper extremity spasticity, the recommendations are for use of aboBoNT-A, incoBoNT-A and onaBoNT-A with level A evidence. For the management of lower extremity spasticity, the recommendations are for use of onaBoNT-A and aboBoNT-A with level A evidence. For the management of chronic migraines, the recommendations are for use of onaBoNT-A to help improve headache-free days, with level A evidence. It is important for the clinician to understand that BoNT is for use in symptomatic control for the underlying neurologic disorder and, at present, has not shown a role in disease modification.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app